Short Interest in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Rises By 64.4%

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 13,469 shares, an increase of 64.4% from the August 15th total of 8,194 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 45,610 shares, the days-to-cover ratio is currently 0.3 days.

Regentis Biomaterials Stock Performance

NYSEAMERICAN:RGNT opened at $1.80 on Thursday. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50. The company’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $2.71.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last posted its quarterly earnings data on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

Institutional Trading of Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.